MCID: BRS099
MIFTS: 57

Breast Ductal Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Breast Ductal Carcinoma

MalaCards integrated aliases for Breast Ductal Carcinoma:

Name: Breast Ductal Carcinoma 12 15
Ductal Breast Carcinoma 55 6 73
Mammary Ductal Carcinoma 73
Carcinoma, Ductal 44
Ductal Carcinoma 73
Duct Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3007
MeSH 44 D044584
SNOMED-CT 68 82711006

Summaries for Breast Ductal Carcinoma

Disease Ontology : 12 A breast carcinoma that derives from the lining of milk ducts.

MalaCards based summary : Breast Ductal Carcinoma, also known as ductal breast carcinoma, is related to comedo carcinoma and renal cell carcinoma, nonpapillary. An important gene associated with Breast Ductal Carcinoma is RAD54L (RAD54 Like), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Epirubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and t cells, and related phenotypes are Decreased cell migration and Decreased viability in esophageal squamous lineage

Related Diseases for Breast Ductal Carcinoma

Diseases related to Breast Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 32.4 ERBB2 ESR1
2 renal cell carcinoma, nonpapillary 32.4 CDH1 EGFR KRT8 MET
3 bile duct cancer 32.4 CCND1 EGFR MET TP53
4 intrahepatic cholangiocarcinoma 32.2 CDH1 CTNNB1 EGFR TP53
5 breast cystic hypersecretory carcinoma 32.0 CDH1 ERBB2
6 cholangiocarcinoma 31.6 CCND1 CDH1 CTNNB1 EGFR ERBB2 KRT8
7 in situ carcinoma 30.9 BRCA1 CDH1 EGFR ERBB2 ESR1 PGR
8 pleomorphic adenoma carcinoma 30.8 ERBB2 TP53
9 pleomorphic adenoma 30.4 AR ERBB2 TP53
10 adenocarcinoma 30.3 CCND1 CDH1 CTNNB1 EGFR ERBB2 TP53
11 renal cell carcinoma, papillary, 1 30.1 ERBB2 MET TP53
12 ductal carcinoma in situ 30.1 AR BRCA1 CCND1 CDH1 EGFR ERBB2
13 breast carcinoma in situ 29.9 BRCA1 EGFR ERBB2 ESR1 MET PGR
14 cystadenocarcinoma 29.9 ERBB2 PGR TP53
15 transitional cell carcinoma 29.8 CDH1 EGFR ERBB2 KRT8 TP53
16 adenoid cystic carcinoma 29.8 CCND1 CDH1 CTNNB1 ERBB2 PGR TP53
17 papillary carcinoma 29.6 CDH1 ERBB2 MET PGR
18 squamous cell carcinoma 29.5 CCND1 CDH1 CTNNB1 EGFR ERBB2 NME1
19 breast disease 29.5 BRCA1 CTSD ERBB2 ESR1 PGR TFF1
20 breast fibroadenoma 29.2 ERBB2 ESR1 KRT8 NME1 PGR
21 bladder urothelial carcinoma 29.1 AR CCND1 CDH1 CTNNB1 ERBB2 TP53
22 breast cancer 27.0 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
23 collecting duct carcinoma 12.6
24 adenosquamous bile duct carcinoma 12.3
25 bile duct carcinoma in situ 12.1
26 nipple duct carcinoma 12.1
27 squamous cell bile duct carcinoma 12.0
28 distal biliary tract carcinoma 11.4
29 biliary tract neoplasm 11.3
30 cribriform carcinoma 11.1
31 klatskin's tumor 11.0
32 extrahepatic bile duct small cell adenocarcinoma 11.0
33 renal cell carcinoma, xp11-associated 11.0
34 extrahepatic bile duct adenocarcinoma 11.0
35 bile duct adenocarcinoma 11.0
36 cerebral convexity meningioma 10.4 CDH1 TP53
37 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
38 adult hepatocellular carcinoma 10.3 CTNNB1 TP53
39 breast papillomatosis 10.3 CCND1 ERBB2
40 breast malignant phyllodes tumor 10.3 PGR TP53
41 childhood hepatocellular carcinoma 10.3 CTNNB1 MET
42 brain ependymoma 10.3 EGFR TP53
43 intracystic papillary adenoma 10.3 ERBB2 PGR
44 breast metaplastic carcinoma 10.3 ERBB2 PGR
45 vulvar benign neoplasm 10.3 ESR1 PGR
46 trigonitis 10.3 ESR1 PGR
47 bartholin's gland benign neoplasm 10.3 ESR1 PGR
48 lung leiomyoma 10.3 ESR1 PGR
49 vulvar leiomyoma 10.3 ESR1 PGR
50 predominantly cortical thymoma 10.3 ESR1 PGR

Graphical network of the top 20 diseases related to Breast Ductal Carcinoma:



Diseases related to Breast Ductal Carcinoma

Symptoms & Phenotypes for Breast Ductal Carcinoma

GenomeRNAi Phenotypes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.65 CTNNB1 CTSD EGFR MET VEGFC
2 Decreased viability in esophageal squamous lineage GR00235-A 9.65 BRCA1 CCND1 CDH1 CTNNB1 ERBB2 ESR1
3 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 CTNNB1 CTSD EGFR ERBB2 VEGFC
4 Increased cell death HMECs cells GR00103-A-0 9.1 BRCA1 CTNNB1 EGFR PGR PIP TP53

MGI Mouse Phenotypes related to Breast Ductal Carcinoma:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
2 cellular MP:0005384 10.46 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
3 homeostasis/metabolism MP:0005376 10.46 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
4 digestive/alimentary MP:0005381 10.44 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
5 endocrine/exocrine gland MP:0005379 10.43 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
6 growth/size/body region MP:0005378 10.42 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
7 immune system MP:0005387 10.42 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
8 mortality/aging MP:0010768 10.4 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
9 hematopoietic system MP:0005397 10.35 AR BRCA1 CCND1 CTNNB1 CTSD EGFR
10 embryo MP:0005380 10.33 AR BRCA1 CDH1 CTNNB1 EGFR ERBB2
11 integument MP:0010771 10.31 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
12 neoplasm MP:0002006 10.27 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
13 limbs/digits/tail MP:0005371 10.18 AR BRCA1 CTNNB1 EGFR ERBB2 ESR1
14 nervous system MP:0003631 10.17 AR BRCA1 CCND1 CTNNB1 CTSD EGFR
15 craniofacial MP:0005382 10.15 AR CCND1 CTNNB1 EGFR ERBB2 MET
16 normal MP:0002873 10.15 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
17 muscle MP:0005369 10.13 AR BRCA1 CTNNB1 EGFR ERBB2 ESR1
18 liver/biliary system MP:0005370 10.11 AR CTNNB1 EGFR ESR1 KRT8 MET
19 no phenotypic analysis MP:0003012 9.95 CDH1 CTNNB1 EGFR ESR1 MET PGR
20 reproductive system MP:0005389 9.93 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
21 renal/urinary system MP:0005367 9.8 AR BRCA1 CTNNB1 EGFR ESR1 MET
22 pigmentation MP:0001186 9.72 AR BRCA1 CTNNB1 EGFR TP53
23 respiratory system MP:0005388 9.56 BRCA1 CCND1 CTNNB1 EGFR ERBB2 ESR1
24 skeleton MP:0005390 9.28 AR BRCA1 CCND1 CTNNB1 EGFR ERBB2

Drugs & Therapeutics for Breast Ductal Carcinoma

Drugs for Breast Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Pertuzumab Approved Phase 3,Phase 2 145040-37-5, 380610-27-5 2540
5
Tamoxifen Approved Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
6
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
7
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
8
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-28-2 5757
9 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 979-32-8
10
Polyestradiol phosphate Approved Phase 3,Phase 2,Not Applicable 28014-46-2
11
Fulvestrant Approved, Investigational Phase 3,Phase 2,Not Applicable 129453-61-8 17756771 104741
12
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
13
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
14
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
15
Carboplatin Approved Phase 2, Phase 3,Phase 3 41575-94-4 10339178 38904 498142
16
Trastuzumab Approved, Investigational Phase 2, Phase 3,Phase 3 180288-69-1 9903
17
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
18
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
19
Toremifene Approved, Investigational Phase 3 89778-26-7 3005573
20
mometasone furoate Approved, Vet_approved Phase 3 83919-23-7
21
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
22
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
23
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
24
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
25
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 657181 3911
26
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
27
Metformin Approved Phase 3 657-24-9 14219 4091
28
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
29
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
30
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
31
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
32
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
33
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Not Applicable 388082-78-8, 231277-92-2 208908 9941095
34 Atamestane Investigational Phase 3 96301-34-7
35 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
36 Antimitotic Agents Phase 3,Phase 2,Phase 1
37 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
38 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
41 Aromatase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
42 Steroid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
43 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
44 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
45 Estrogen Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
47 Citrate Phase 3,Phase 2,Phase 1,Not Applicable
48 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable
49 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
50 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 165)
# Name Status NCT ID Phase Drugs
1 Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer Unknown status NCT01349842 Phase 3
2 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Unknown status NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
3 Radiation Therapy in Treating Women With Early-Stage Breast Cancer Who Have Undergone Breast Conservation Surgery Unknown status NCT00814567 Phase 3
4 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
5 Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer Completed NCT00002967 Phase 3 cyclophosphamide;doxorubicin hydrochloride;octreotide pamoate;tamoxifen citrate
6 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
7 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
8 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
9 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
10 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
11 Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer Completed NCT00044291 Phase 3 atamestane;toremifene;letrozole;aromatase inhibition
12 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
13 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
14 Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 Recruiting NCT02620280 Phase 3 Carboplatin;Abraxane;MPDL3280A;Anthra
15 Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women Recruiting NCT03201861 Phase 3 Paclitaxel, Cisplatin;EC to docetaxel or paclitaxel
16 Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
17 Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Recruiting NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
18 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
19 Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer Recruiting NCT03414970 Phase 3
20 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
21 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
22 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
23 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
24 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
25 Oxybutynin Chloride in Managing Hot Flashes Active, not recruiting NCT02961790 Phase 3 Oxybutynin Chloride
26 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
27 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
28 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
29 Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer Terminated NCT00267553 Phase 3 Atamestane;toremifene;letrozole
30 The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer Terminated NCT00097344 Phase 3 Atamestane;Toremifene;Letrozole;Aromatase inhibition;Estrogen receptor blocker
31 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
32 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
33 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
34 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
35 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Completed NCT01439711 Phase 2 letrozole
36 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Completed NCT02150525 Phase 2
37 Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Completed NCT02199418 Phase 2 Paclitaxel;Cisplatin
38 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
39 Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy Completed NCT00843167 Phase 2
40 Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer Completed NCT00960336 Phase 2 pegylated liposomal doxorubicin hydrochloride
41 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Completed NCT00182793 Phase 2 carboplatin;cyclophosphamide;melphalan;thiotepa
42 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
43 Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer Completed NCT00002873 Phase 1, Phase 2
44 Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Completed NCT01869764 Phase 2
45 Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer Completed NCT00870415 Phase 2
46 Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer Completed NCT00616967 Phase 2 carboplatin;paclitaxel albumin-stabilized nanoparticle formulation;vorinostat
47 Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer Completed NCT00096343 Phase 2 carboplatin;paclitaxel
48 Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
49 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
50 Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer Completed NCT00354640 Phase 2 anastrozole;simvastatin

Search NIH Clinical Center for Breast Ductal Carcinoma

Cochrane evidence based reviews: carcinoma, ductal

Genetic Tests for Breast Ductal Carcinoma

Anatomical Context for Breast Ductal Carcinoma

MalaCards organs/tissues related to Breast Ductal Carcinoma:

41
Breast, Lymph Node, T Cells, Endothelial, Kidney, Liver, Thyroid

Publications for Breast Ductal Carcinoma

Articles related to Breast Ductal Carcinoma:

(show top 50) (show all 328)
# Title Authors Year
1
Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. ( 29955142 )
2018
2
Development of ipsilateral chest wall spindle cell carcinoma in a patient with invasive ductal breast carcinoma during postoperative adjuvant therapy: A case report. ( 29742739 )
2018
3
Breast lymphoma occurring after an invasive ductal breast carcinoma developed in the same area: A case report and literature review. ( 29657120 )
2018
4
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. ( 29394917 )
2018
5
Overtreatment in surgery - does it concern also the patients with ductal breast carcinoma in situ. ( 29513252 )
2018
6
Aberrant Expression of PIWIL1 and PIWIL2 and Their Clinical Significance in Ductal Breast Carcinoma. ( 29599319 )
2018
7
Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery. ( 29709458 )
2018
8
Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ. ( 29694611 )
2018
9
A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk. ( 30054280 )
2018
10
Computational Feasibility Analysis of Electrochemotherapy With Novel Needle-Electrode Arrays for the Treatment of Invasive Breast Ductal Carcinoma. ( 30157721 )
2018
11
A clinical application of dynamic contrast-enhanced CT (DCE-CT) in patients with variously differentiated breast ductal carcinoma. ( 30198882 )
2018
12
Immunohistochemical Expression of Nanog and Its Relation with Clinicopathologic Characteristics in Breast Ductal Carcinoma ( 30220190 )
2018
13
Functional Role of microRNAs in the Progression of Breast Ductal Carcinoma in situ. ( 30273605 )
2018
14
Morphologic and Molecular Features of Breast Ductal Carcinoma In Situ. ( 30385094 )
2018
15
Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). ( 30410060 )
2018
16
Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. ( 30429518 )
2018
17
Possible predictive role of cancer/testis antigens in breast ductal carcinoma in situ. ( 30546463 )
2018
18
Corrigendum: Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. ( 30068734 )
2018
19
Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases. ( 30151336 )
2018
20
Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular stress. ( 30224719 )
2018
21
Colonic metastasis from infiltrating ductal breast carcinoma in a male patient: A case report. ( 30513496 )
2018
22
Endometrial Metastasis from Ductal Breast Carcinoma: A Case Report with Literature Review. ( 29700276 )
2018
23
Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. ( 29739984 )
2018
24
The Role of CHI3L1 Expression in Angiogenesis in Invasive Ductal Breast Carcinoma. ( 29848684 )
2018
25
Association of conventional ultrasound, elastography and clinicopathological factors with axillary lymph node status in invasive ductal breast carcinoma with sizes > 10 mm. ( 29416814 )
2018
26
Tenascin C is a prognostic determinant and potential cancer-associated fibroblasts marker for breast ductal carcinoma. ( 28223108 )
2017
27
Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: a meta-analysis. ( 28415667 )
2017
28
(18)F-fluorodeoxyglucose uptake as predictor for invasion in preoperatively diagnosed breast ductal carcinoma in situ: Significance in cases without mass formation. ( 28781782 )
2017
29
Gli1 is a potential cancer stem cell marker and predicts poor prognosis in ductal breast carcinoma. ( 28965964 )
2017
30
IQ-domain GTPase-activating protein 1 promotes the malignant phenotype of invasive ductal breast carcinoma via canonical Wnt pathway. ( 28618949 )
2017
31
The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study. ( 29096155 )
2017
32
Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ. ( 28885232 )
2017
33
Down-regulation of C35 decreased the cell viability and migration of breast ductal carcinoma cells. ( 28859163 )
2017
34
Spatial distribution of mast cells and macrophages around tumor glands in human breast ductal carcinoma. ( 28756894 )
2017
35
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. ( 28286675 )
2017
36
Quantitatively characterizing the microstructural features of breast ductal carcinoma tissues in different progression stages by Mueller matrix microscope. ( 28856041 )
2017
37
Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. ( 28338653 )
2017
38
Management of breast ductal carcinoma in situ in Catalonia, Spain: Results from the Grup Oncologic CalalA -OccitA -Catalonia survey with 9-year follow up. ( 28806663 )
2017
39
Correlation Between Expression of Twist and Podoplanin in Ductal Breast Carcinoma. ( 28982860 )
2017
40
Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma. ( 28087477 )
2017
41
Breast ductal carcinoma in situ in an unscreened population: presentation, diagnosis and management at a single tertiary centre. ( 28876551 )
2017
42
Identifying progression predictors of breast ductal carcinoma in situ. ( 27864452 )
2017
43
Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features. ( 28611201 )
2017
44
A single nucleotide polymorphism in codon F31I and V57I of the AURKA gene in invasive ductal breast carcinoma in Middle East. ( 28906374 )
2017
45
High expression of heat shock protein 10 correlates negatively with estrogen/progesterone receptor status and predicts poor prognosis in invasive ductal breast carcinoma. ( 27993580 )
2017
46
Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. ( 28326600 )
2017
47
Synchronous papillary thyroid carcinoma and breast ductal carcinoma: A rare case report and literature review. ( 28207532 )
2017
48
Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. ( 28514723 )
2017
49
T-cell immunoglobulin mucin-3 expression in invasive ductal breast carcinoma: Clinicopathological correlations and association with tumor infiltration by cytotoxic lymphocytes. ( 28855989 )
2017
50
Prognostic Value of Percentage Change in Metabolic Parameters as Measured by Dual-Time Point 18F-FDG PET/CT in Premenopausal Women with Invasive Ductal Breast Carcinoma. ( 28498790 )
2017

Variations for Breast Ductal Carcinoma

ClinVar genetic disease variations for Breast Ductal Carcinoma:

6 (show top 50) (show all 298)
# Gene Variation Type Significance SNP ID Assembly Location
1 RAD54L NM_001142548.1(RAD54L): c.973G> A (p.Gly325Arg) single nucleotide variant Pathogenic rs121908690 GRCh37 Chromosome 1, 46733212: 46733212
2 RAD54L NM_001142548.1(RAD54L): c.973G> A (p.Gly325Arg) single nucleotide variant Pathogenic rs121908690 GRCh38 Chromosome 1, 46267540: 46267540
3 BRCA2 NM_000059.3(BRCA2): c.1114A> C (p.Asn372His) single nucleotide variant Benign rs144848 GRCh37 Chromosome 13, 32906729: 32906729
4 BRCA2 NM_000059.3(BRCA2): c.1114A> C (p.Asn372His) single nucleotide variant Benign rs144848 GRCh38 Chromosome 13, 32332592: 32332592
5 BRCA1 NM_007294.3(BRCA1): c.1067A> G (p.Gln356Arg) single nucleotide variant Benign rs1799950 GRCh37 Chromosome 17, 41246481: 41246481
6 BRCA1 NM_007294.3(BRCA1): c.1067A> G (p.Gln356Arg) single nucleotide variant Benign rs1799950 GRCh38 Chromosome 17, 43094464: 43094464
7 BRCA2 NM_000059.3(BRCA2): c.7397C= (p.Ala2466=) single nucleotide variant Benign rs169547 GRCh37 Chromosome 13, 32929387: 32929387
8 BRCA2 NM_000059.3(BRCA2): c.7397C= (p.Ala2466=) single nucleotide variant Benign rs169547 GRCh38 Chromosome 13, 32355250: 32355250
9 SYT6 NM_001270805.1(SYT6): c.1216G> A (p.Ala406Thr) single nucleotide variant Uncertain significance rs142164979 GRCh37 Chromosome 1, 114640393: 114640393
10 SYT6 NM_001270805.1(SYT6): c.1216G> A (p.Ala406Thr) single nucleotide variant Uncertain significance rs142164979 GRCh38 Chromosome 1, 114097771: 114097771
11 ZDBF2 NM_020923.2(ZDBF2): c.5795G> A (p.Arg1932His) single nucleotide variant Uncertain significance rs763186071 GRCh37 Chromosome 2, 207175047: 207175047
12 ZDBF2 NM_020923.2(ZDBF2): c.5795G> A (p.Arg1932His) single nucleotide variant Uncertain significance rs763186071 GRCh38 Chromosome 2, 206310323: 206310323
13 YEATS2 NM_018023.4(YEATS2): c.3131C> T (p.Pro1044Leu) single nucleotide variant Uncertain significance rs376025260 GRCh37 Chromosome 3, 183515744: 183515744
14 YEATS2 NM_018023.4(YEATS2): c.3131C> T (p.Pro1044Leu) single nucleotide variant Uncertain significance rs376025260 GRCh38 Chromosome 3, 183797956: 183797956
15 PHF24 NM_001304333.2(PHF24): c.242G> A (p.Arg81Gln) single nucleotide variant Uncertain significance rs374394658 GRCh37 Chromosome 9, 34971537: 34971537
16 PHF24 NM_001304333.2(PHF24): c.242G> A (p.Arg81Gln) single nucleotide variant Uncertain significance rs374394658 GRCh38 Chromosome 9, 34971540: 34971540
17 CCDC180 NM_020893.3(CCDC180): c.1975C> G (p.Pro659Ala) single nucleotide variant Uncertain significance rs869025225 GRCh37 Chromosome 9, 100092618: 100092618
18 CCDC180 NM_020893.3(CCDC180): c.1975C> G (p.Pro659Ala) single nucleotide variant Uncertain significance rs869025225 GRCh38 Chromosome 9, 97330336: 97330336
19 CNNM1 NM_020348.2(CNNM1): c.957G> C (p.Glu319Asp) single nucleotide variant Uncertain significance rs869025226 GRCh37 Chromosome 10, 101090101: 101090101
20 CNNM1 NM_020348.2(CNNM1): c.957G> C (p.Glu319Asp) single nucleotide variant Uncertain significance rs869025226 GRCh38 Chromosome 10, 99330344: 99330344
21 MICAL2 NM_014632.3(MICAL2): c.3131A> G (p.Asp1044Gly) single nucleotide variant Uncertain significance rs869025227 GRCh37 Chromosome 11, 12278507: 12278507
22 MICAL2 NM_014632.3(MICAL2): c.3131A> G (p.Asp1044Gly) single nucleotide variant Uncertain significance rs869025227 GRCh38 Chromosome 11, 12256960: 12256960
23 KDM4E NM_001161630.1(KDM4E): c.1493A> G (p.Asn498Ser) single nucleotide variant Uncertain significance rs869025228 GRCh37 Chromosome 11, 94760214: 94760214
24 KDM4E NM_001161630.1(KDM4E): c.1493A> G (p.Asn498Ser) single nucleotide variant Uncertain significance rs869025228 GRCh38 Chromosome 11, 95027050: 95027050
25 TSPAN8 NM_004616.2(TSPAN8): c.528T> A (p.Asp176Glu) single nucleotide variant Uncertain significance rs869025229 GRCh37 Chromosome 12, 71526521: 71526521
26 TSPAN8 NM_004616.2(TSPAN8): c.528T> A (p.Asp176Glu) single nucleotide variant Uncertain significance rs869025229 GRCh38 Chromosome 12, 71132741: 71132741
27 CORO6 NM_032854.3(CORO6): c.1348G> A (p.Val450Met) single nucleotide variant Uncertain significance rs772136445 GRCh37 Chromosome 17, 27942821: 27942821
28 CORO6 NM_032854.3(CORO6): c.1348G> A (p.Val450Met) single nucleotide variant Uncertain significance rs772136445 GRCh38 Chromosome 17, 29615803: 29615803
29 NOTCH3 NM_000435.2(NOTCH3): c.5161T> A (p.Trp1721Arg) single nucleotide variant Uncertain significance rs869025230 GRCh37 Chromosome 19, 15280935: 15280935
30 NOTCH3 NM_000435.2(NOTCH3): c.5161T> A (p.Trp1721Arg) single nucleotide variant Uncertain significance rs869025230 GRCh38 Chromosome 19, 15170124: 15170124
31 CPAMD8 NM_015692.3(CPAMD8): c.4156G> A (p.Ala1386Thr) single nucleotide variant Uncertain significance rs869025231 GRCh37 Chromosome 19, 17017774: 17017774
32 CPAMD8 NM_015692.3(CPAMD8): c.4156G> A (p.Ala1386Thr) single nucleotide variant Uncertain significance rs869025231 GRCh38 Chromosome 19, 16906964: 16906964
33 ZNF420 NM_001329517.1(ZNF420): c.149A> G (p.Asn50Ser) single nucleotide variant Uncertain significance rs771433810 GRCh37 Chromosome 19, 37618255: 37618255
34 ZNF420 NM_001329517.1(ZNF420): c.149A> G (p.Asn50Ser) single nucleotide variant Uncertain significance rs771433810 GRCh38 Chromosome 19, 37127353: 37127353
35 ZNF473 NM_015428.3(ZNF473): c.2359A> T (p.Arg787Ter) single nucleotide variant Uncertain significance rs869025232 GRCh37 Chromosome 19, 50550059: 50550059
36 ZNF473 NM_015428.3(ZNF473): c.2359A> T (p.Arg787Ter) single nucleotide variant Uncertain significance rs869025232 GRCh38 Chromosome 19, 50046802: 50046802
37 KRTAP10-3 NM_198696.2(KRTAP10-3): c.7A> G (p.Thr3Ala) single nucleotide variant Uncertain significance rs452472 GRCh37 Chromosome 21, 45978592: 45978592
38 KRTAP10-3 NM_198696.2(KRTAP10-3): c.7A> G (p.Thr3Ala) single nucleotide variant Uncertain significance rs452472 GRCh38 Chromosome 21, 44558709: 44558709
39 CCDC71L NM_175884.5(CCDC71L): c.478A> C (p.Ser160Arg) single nucleotide variant Uncertain significance rs869025233 GRCh37 Chromosome 7, 106300865: 106300865
40 CCDC71L NM_175884.5(CCDC71L): c.478A> C (p.Ser160Arg) single nucleotide variant Uncertain significance rs869025233 GRCh38 Chromosome 7, 106660419: 106660419
41 HTRA2 NM_013247.4(HTRA2): c.695T> A (p.Leu232Gln) single nucleotide variant Uncertain significance rs869025234 GRCh37 Chromosome 2, 74757932: 74757932
42 HTRA2 NM_013247.4(HTRA2): c.695T> A (p.Leu232Gln) single nucleotide variant Uncertain significance rs869025234 GRCh38 Chromosome 2, 74530805: 74530805
43 LRAT NM_004744.4(LRAT): c.78T> A (p.Ser26Arg) single nucleotide variant Uncertain significance rs869025235 GRCh37 Chromosome 4, 155665556: 155665556
44 LRAT NM_004744.4(LRAT): c.78T> A (p.Ser26Arg) single nucleotide variant Uncertain significance rs869025235 GRCh38 Chromosome 4, 154744404: 154744404
45 CREB3 NM_006368.4(CREB3): c.823T> G (p.Tyr275Asp) single nucleotide variant Uncertain significance rs869025236 GRCh37 Chromosome 9, 35736430: 35736430
46 CREB3 NM_006368.4(CREB3): c.823T> G (p.Tyr275Asp) single nucleotide variant Uncertain significance rs869025236 GRCh38 Chromosome 9, 35736433: 35736433
47 ALOX5 NM_000698.4(ALOX5): c.490T> G (p.Leu164Val) single nucleotide variant Uncertain significance rs869025237 GRCh37 Chromosome 10, 45907697: 45907697
48 ALOX5 NM_000698.4(ALOX5): c.490T> G (p.Leu164Val) single nucleotide variant Uncertain significance rs869025237 GRCh38 Chromosome 10, 45412249: 45412249
49 KNDC1 NM_152643.7(KNDC1): c.2914G> T (p.Glu972Ter) single nucleotide variant Uncertain significance rs869025238 GRCh37 Chromosome 10, 135013889: 135013889
50 KNDC1 NM_152643.7(KNDC1): c.2914G> T (p.Glu972Ter) single nucleotide variant Uncertain significance rs869025238 GRCh38 Chromosome 10, 133200385: 133200385

Cosmic variations for Breast Ductal Carcinoma:

9 (show top 50) (show all 5305)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM51177 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.1563G>A p.K521K 10:73797261-73797261 16
2 COSM6937481 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1406C>T p.S469L 23:15823199-15823199 16
3 COSM6925955 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.267G>C p.K89N 23:15803751-15803751 16
4 COSM6963999 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1312G>T p.G438C 23:15823105-15823105 16
5 COSM6974238 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1084G>A p.E362K 23:15822877-15822877 16
6 COSM6953912 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.989A>G p.H330R 23:15822782-15822782 16
7 COSM32591 ZNHIT2 breast,NS,carcinoma,ductal carcinoma c.175G>C p.A59P 11:65117479-65117479 16
8 COSM50437 ZNF830 breast,NS,carcinoma,ductal carcinoma c.136A>G p.N46D 17:34961702-34961702 16
9 COSM33456 ZNF668 breast,NS,carcinoma,ductal carcinoma c.196G>A p.A66T 16:31064264-31064264 16
10 COSM33234 ZNF668 breast,NS,carcinoma,ductal carcinoma c.992C>G p.T331R 16:31061936-31061936 16
11 COSM33435 ZNF668 breast,NS,carcinoma,ductal carcinoma c.856G>A p.G286S 16:31062072-31062072 16
12 COSM33584 ZNF646 breast,NS,carcinoma,ductal carcinoma c.4010A>T p.N1337I 16:31080334-31080334 16
13 COSM32207 ZNF644 breast,NS,carcinoma,ductal carcinoma c.157G>C p.E53Q 1:90941197-90941197 16
14 COSM32635 ZNF569 breast,NS,carcinoma,ductal carcinoma c.85C>G p.Q29E 19:37426309-37426309 16
15 COSM32954 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 16
16 COSM33530 ZNF438 breast,NS,carcinoma,ductal carcinoma c.1143G>C p.K381N 10:30849262-30849262 16
17 COSM32744 ZNF318 breast,NS,carcinoma,ductal carcinoma c.3820G>C p.G1274R 6:43340178-43340178 16
18 COSM32924 ZNF281 breast,NS,carcinoma,ductal carcinoma c.1580T>C p.I527T 1:200408126-200408126 16
19 COSM33029 ZNF277 breast,NS,carcinoma,ductal carcinoma c.994A>T p.I332L 7:112339870-112339870 16
20 COSM32751 ZNF277 breast,NS,carcinoma,ductal carcinoma c.1335G>C p.L445F 7:112342711-112342711 16
21 COSM32755 ZNF25 breast,NS,carcinoma,ductal carcinoma c.61G>A p.E21K 10:37957501-37957501 16
22 COSM33510 ZNF22 breast,NS,carcinoma,ductal carcinoma c.386A>T p.H129L 10:45003754-45003754 16
23 COSM32252 ZNF10 breast,NS,carcinoma,ductal carcinoma c.257-3C>G p.? 12:133155500-133155500 16
24 COSM50670 ZMIZ2 breast,NS,carcinoma,ductal carcinoma c.491C>G p.A164G 7:44757500-44757500 16
25 COSM32244 ZMIZ1 breast,NS,carcinoma,ductal carcinoma c.1651C>G p.L551V 10:79298565-79298565 16
26 COSM50422 ZKSCAN2 breast,NS,carcinoma,ductal carcinoma c.1258G>A p.E420K 16:25246938-25246938 16
27 COSM32555 ZIC3 breast,NS,carcinoma,ductal carcinoma c.649C>G p.P217A 23:137567340-137567340 16
28 COSM33562 ZFYVE26 breast,NS,carcinoma,ductal carcinoma c.3491C>A p.A1164E 14:67785091-67785091 16
29 COSM50767 ZFHX4 breast,NS,carcinoma,ductal carcinoma c.5524G>A p.V1842M 8:76852445-76852445 16
30 COSM50766 ZFHX4 breast,NS,carcinoma,ductal carcinoma c.9752C>G p.A3251G 8:76863466-76863466 16
31 COSM3276869 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.4750C>T p.Q1584* 16:72797932-72797932 16
32 COSM6941446 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.9095A>C p.K3032T 16:72793587-72793587 16
33 COSM6845183 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.2143C>T p.R715* 16:72958003-72958003 16
34 COSM6933756 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.1444G>A p.E482K 16:72958702-72958702 16
35 COSM6946536 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.7667C>T p.A2556V 16:72795015-72795015 16
36 COSM6980784 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.8798C>G p.S2933C 16:72793884-72793884 16
37 COSM6942666 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.6871C>T p.Q2291* 16:72795811-72795811 16
38 COSM6940614 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.2714C>G p.A905G 16:72957432-72957432 16
39 COSM6933933 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.4468G>A p.E1490K 16:72798214-72798214 16
40 COSM6953107 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.611T>G p.F204C 16:72959535-72959535 16
41 COSM6954458 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.8043G>C p.K2681N 16:72794639-72794639 16
42 COSM4984432 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.3757C>T p.R1253C 16:72811684-72811684 16
43 COSM6934678 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.10111C>A p.L3371M 16:72788165-72788165 16
44 COSM6946621 ZFHX3 breast,NS,carcinoma,ductal carcinoma c.7789C>A p.P2597T 16:72794893-72794893 16
45 COSM50608 ZFC3H1 breast,NS,carcinoma,ductal carcinoma c.2306C>A p.A769D 12:71634758-71634758 16
46 COSM32934 ZDHHC4 breast,NS,carcinoma,ductal carcinoma c.310C>T p.P104S 7:6582191-6582191 16
47 COSM33432 ZCCHC24 breast,NS,carcinoma,ductal carcinoma c.725G>C p.*242S 10:79386346-79386346 16
48 COSM32774 ZCCHC14 breast,NS,carcinoma,ductal carcinoma c.868C>G p.L290V 16:87417564-87417564 16
49 COSM50385 ZBTB39 breast,NS,carcinoma,ductal carcinoma c.295G>A p.V99I 12:57004623-57004623 16
50 COSM33515 ZBTB3 breast,NS,carcinoma,ductal carcinoma c.1271A>T p.H424L 11:62752544-62752544 16

Copy number variations for Breast Ductal Carcinoma from CNVD:

7 (show all 33)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 50888 11 119630000 120260000 Deletion Ductal carcinoma
2 57116 11 63100000 76700000 Amplification CCND1 Ductal carcinoma
3 58629 11 68930000 70160000 Gain Ductal carcinoma
4 58724 11 69230000 69780000 Gain Ductal carcinoma
5 59882 11 78860000 79330000 Deletion Ductal carcinoma
6 60225 11 84000000 88080000 Deletion Ductal carcinoma
7 60766 11 91240000 95940000 Deletion Ductal carcinoma
8 66468 12 2966849 2986303 Copy number FOXM1 Ductal carcinoma
9 98103 16 15360000 17700000 Gain Ductal carcinoma
10 99317 16 25030000 27880000 Gain Ductal carcinoma
11 101507 16 40000 40090000 Gain Ductal carcinoma
12 107663 17 16530000 18020000 Deletion Ductal carcinoma
13 109740 17 28800000 35400000 Amplification ERBB2 Ductal carcinoma
14 116392 17 6500000 10700000 Copy number TP53 Ductal carcinoma
15 117043 17 70920000 72340000 Gain Ductal carcinoma
16 126771 19 20810000 63790000 Gain Ductal carcinoma
17 127047 19 23780000 51950000 Gain Ductal carcinoma
18 128079 19 39420000 40350000 Gain Ductal carcinoma
19 131070 19 52760000 63790000 Gain Ductal carcinoma
20 153161 20 34860000 62370000 Gain Ductal carcinoma
21 153748 20 41100000 62435964 Amplification BMP7 Ductal carcinoma
22 166731 3 107740000 107880000 Deletion Ductal carcinoma
23 166830 3 108620000 110660000 Deletion Ductal carcinoma
24 167069 3 112930000 115910000 Deletion Ductal carcinoma
25 179845 3 99790000 104540000 Deletion Ductal carcinoma
26 196641 5 170120000 170210000 Gain Ductal carcinoma
27 196700 5 170690000 172750000 Gain Ductal carcinoma
28 215548 6 77380000 82650000 Deletion Ductal carcinoma
29 231989 8 110000 5150000 Deletion Ductal carcinoma
30 233354 8 124380000 129070000 Gain Ductal carcinoma
31 234986 8 140450000 141700000 Gain Ductal carcinoma
32 238072 8 29700000 38500000 Amplification FGFR1 Ductal carcinoma
33 239766 8 41480000 42480000 Gain Ductal carcinoma

Expression for Breast Ductal Carcinoma

Search GEO for disease gene expression data for Breast Ductal Carcinoma.

Pathways for Breast Ductal Carcinoma

Pathways related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
2
Show member pathways
13.45 AR CCND1 EGFR ERBB2 MET PIP
3
Show member pathways
13.33 CDH1 CTNNB1 EGFR ERBB2 MET PIP
4
Show member pathways
13.31 CDH1 CTNNB1 EGFR ERBB2 ESR1 MET
5
Show member pathways
13.07 CTSD EGFR ESR1 PGR TFF1 VEGFC
6
Show member pathways
12.95 BRCA1 CCND1 CTNNB1 EGFR ERBB2 MET
7
Show member pathways
12.93 CCND1 CTNNB1 EGFR ERBB2 MET VEGFC
8
Show member pathways
12.87 AR CCND1 CDH1 CTNNB1 EGFR ERBB2
9 12.8 EGFR ERBB2 MET TP53 VEGFC
10
Show member pathways
12.76 CDH1 CTNNB1 EGFR MET VEGFC
11
Show member pathways
12.73 CDH1 CTNNB1 ERBB2 ESR1 MET TP53
12
Show member pathways
12.59 BRCA1 CCND1 CDH1 EGFR ERBB2 ESR1
13 12.58 AR CCND1 CDH1 CTNNB1 EGFR ERBB2
14
Show member pathways
12.55 CCND1 CDH1 CTNNB1 EGFR ERBB2 TP53
15
Show member pathways
12.51 CCND1 EGFR ERBB2 MET TP53
16 12.5 BRCA1 CCND1 EGFR ERBB2 MET TP53
17
Show member pathways
12.46 CTNNB1 EGFR ERBB2 MET TP53
18 12.44 CCND1 CDH1 CTNNB1 TP53
19
Show member pathways
12.41 CDH1 CTNNB1 EGFR ERBB2 MET VEGFC
20
Show member pathways
12.34 CCND1 EGFR ERBB2 ESR1 TFF1
21
Show member pathways
12.32 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
22
Show member pathways
12.26 BRCA1 CCND1 ESR1 PGR
23
Show member pathways
12.23 CCND1 EGFR ERBB2 MET TP53
24 12.21 CCND1 CDH1 CTNNB1 EGFR TP53
25 12.17 EGFR ERBB2 MET VEGFC
26 12.16 CCND1 EGFR ERBB2 MET TP53
27
Show member pathways
12.12 BRCA1 CDH1 EGFR MET VEGFC
28
Show member pathways
12.12 AR CCND1 CTNNB1 EGFR ERBB2
29 12.1 CTSD EGFR MET TP53
30 12.1 CCND1 CTNNB1 EGFR ERBB2 ESR1 MET
31 12.08 CDH1 CTNNB1 MET NME1
32 12.02 CCND1 CTNNB1 ESR1 TP53
33 12.02 CCND1 CTNNB1 ERBB2 TP53
34 12 CCND1 CTNNB1 EGFR TP53
35
Show member pathways
11.98 EGFR ERBB2 ESR1 PGR
36
Show member pathways
11.89 CDH1 CTNNB1 EGFR MET
37
Show member pathways
11.88 EGFR ERBB2 ESR1
38
Show member pathways
11.87 AR ESR1 PGR
39 11.81 AR CCND1 CDH1 CTNNB1
40 11.79 AR BRCA1 CCND1 CTNNB1 EGFR
41 11.78 CDH1 CTNNB1 MET
42 11.77 BRCA1 ERBB2 TP53
43
Show member pathways
11.75 CCND1 EGFR ESR1
44 11.74 CTNNB1 EGFR ERBB2
45 11.72 BRCA1 ERBB2 TP53
46 11.72 CCND1 EGFR ESR1
47 11.71 EGFR ERBB2 MET TP53
48 11.68 BRCA1 CCND1 ERBB2
49 11.67 CCND1 CDH1 EGFR ERBB2 TP53
50 11.62 AR BRCA1 CCND1 CTNNB1

GO Terms for Breast Ductal Carcinoma

Cellular components related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 9.26 CDH1 CTNNB1
2 protein-containing complex GO:0032991 9.17 AR BRCA1 CTNNB1 EGFR ESR1 RAD54L
3 basal plasma membrane GO:0009925 9.13 EGFR ERBB2 MET
4 nucleus GO:0005634 10.17 AR BRCA1 CCND1 CTNNB1 EGFR ERBB2
5 cytoplasm GO:0005737 10.03 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR

Biological processes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 protein deubiquitination GO:0016579 9.99 AR BRCA1 ESR1 TP53
2 negative regulation of gene expression GO:0010629 9.98 CTNNB1 ESR1 NME1 PGR
3 positive regulation of gene expression GO:0010628 9.95 AR BRCA1 CTNNB1 ERBB2 PIP TP53
4 positive regulation of protein phosphorylation GO:0001934 9.93 CCND1 EGFR ERBB2 VEGFC
5 regulation of apoptotic process GO:0042981 9.93 BRCA1 CTNNB1 ESR1 NME1 TP53
6 cell proliferation GO:0008283 9.93 AR CTNNB1 EGFR ERBB2 MET TP53
7 transcription initiation from RNA polymerase II promoter GO:0006367 9.91 AR CCND1 ESR1 PGR
8 positive regulation of protein kinase B signaling GO:0051897 9.91 EGFR ERBB2 ESR1 MET
9 positive regulation of transcription, DNA-templated GO:0045893 9.91 AR BRCA1 CDH1 CTNNB1 EGFR ESR1
10 liver development GO:0001889 9.85 CCND1 EGFR MET
11 phosphatidylinositol phosphorylation GO:0046854 9.85 EGFR ERBB2 ESR1 MET
12 cellular response to drug GO:0035690 9.83 EGFR NME1 TP53
13 response to estrogen GO:0043627 9.83 BRCA1 CCND1 ESR1
14 cellular response to growth factor stimulus GO:0071363 9.81 CTNNB1 EGFR ERBB2
15 response to estradiol GO:0032355 9.81 CCND1 CTNNB1 EGFR ESR1
16 steroid hormone mediated signaling pathway GO:0043401 9.79 AR ESR1 PGR
17 androgen receptor signaling pathway GO:0030521 9.77 AR BRCA1 CTNNB1
18 response to drug GO:0042493 9.73 CCND1 CDH1 CTNNB1 NME1 RAD54L VEGFC
19 positive regulation of cell cycle arrest GO:0071158 9.7 BRCA1 FAP TP53
20 cellular process GO:0009987 9.69 AR CTNNB1
21 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.69 BRCA1 TP53
22 morphogenesis of embryonic epithelium GO:0016331 9.68 CTNNB1 VEGFC
23 Leydig cell differentiation GO:0033327 9.67 AR CCND1
24 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.67 ESR1 TP53
25 positive regulation of transcription by RNA polymerase III GO:0045945 9.67 AR ERBB2
26 DNA strand renaturation GO:0000733 9.66 RAD54L TP53
27 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.66 EGFR TP53
28 mitotic G1 DNA damage checkpoint GO:0031571 9.65 CCND1 TP53
29 positive regulation of execution phase of apoptosis GO:1900119 9.64 FAP TP53
30 negative regulation of ERBB signaling pathway GO:1901185 9.62 EGFR ERBB2
31 positive regulation of epithelial cell proliferation GO:0050679 9.62 EGFR ERBB2 NME1 VEGFC
32 epithelial cell differentiation involved in prostate gland development GO:0060742 9.59 AR CTNNB1
33 morphogenesis of an epithelial fold GO:0060571 9.58 AR EGFR
34 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 9.58 AR CTNNB1
35 mammary gland alveolus development GO:0060749 9.58 AR CCND1 ESR1
36 response to UV-A GO:0070141 9.57 CCND1 EGFR
37 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.56 AR PGR
38 positive regulation of MAPK cascade GO:0043410 9.55 AR CTNNB1 EGFR ERBB2 MET
39 entry of bacterium into host cell GO:0035635 9.13 CDH1 CTNNB1 MET
40 cellular response to indole-3-methanol GO:0071681 8.8 BRCA1 CDH1 CTNNB1
41 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 AR BRCA1 CTNNB1 EGFR ESR1 MET
42 positive regulation of cell proliferation GO:0008284 10.09 AR CCND1 CTNNB1 EGFR VEGFC
43 negative regulation of cell proliferation GO:0008285 10.04 AR CTNNB1 NME1 TFF1 TP53
44 cell differentiation GO:0030154 10.03 CTNNB1 EGFR ERBB2 MET NME1 TFF1

Molecular functions related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.93 CCND1 CTNNB1 EGFR ESR1 TP53
2 chromatin binding GO:0003682 9.91 AR CTNNB1 EGFR ESR1 TP53
3 protein dimerization activity GO:0046983 9.83 AR ERBB2 FAP PIP
4 transcription factor binding GO:0008134 9.83 AR CCND1 CTNNB1 ESR1 TP53
5 identical protein binding GO:0042802 9.81 BRCA1 CDH1 EGFR ERBB2 ESR1 MET
6 beta-catenin binding GO:0008013 9.74 AR CDH1 ESR1
7 ATPase binding GO:0051117 9.73 AR ESR1 PGR
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.67 EGFR ERBB2 MET
9 RNA polymerase II transcription factor binding GO:0001085 9.65 AR CTNNB1 TP53
10 steroid hormone receptor activity GO:0003707 9.63 AR ESR1 PGR
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.62 EGFR ERBB2 ESR1 MET
12 nuclear receptor activity GO:0004879 9.58 AR ESR1 PGR
13 nitric-oxide synthase regulator activity GO:0030235 9.55 EGFR ESR1
14 steroid binding GO:0005496 9.54 AR ESR1 PGR
15 protein phosphatase binding GO:0019903 9.35 CTNNB1 EGFR ERBB2 MET TP53
16 enzyme binding GO:0019899 9.28 AR BRCA1 CCND1 CTNNB1 EGFR ESR1
17 protein binding GO:0005515 10.23 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD

Sources for Breast Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....